108 related articles for article (PubMed ID: 9365997)
1. Treatment of tardive dyskinesia.
Egan MF; Apud J; Wyatt RJ
Schizophr Bull; 1997; 23(4):583-609. PubMed ID: 9365997
[TBL] [Abstract][Full Text] [Related]
2. Neurobiological mechanisms associated with antipsychotic drug-induced dystonia.
Loonen AJ; Ivanova SA
J Psychopharmacol; 2021 Jan; 35(1):3-14. PubMed ID: 32900259
[TBL] [Abstract][Full Text] [Related]
3. Tardive dyskinesia: therapeutic options for an increasingly common disorder.
Cloud LJ; Zutshi D; Factor SA
Neurotherapeutics; 2014 Jan; 11(1):166-76. PubMed ID: 24310603
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic-induced acute laryngeal dystonia: A systematic review of case reports.
Maguire PA; Brazel M; Looi JCL
Schizophr Res; 2024 Feb; 264():248-262. PubMed ID: 38185029
[TBL] [Abstract][Full Text] [Related]
5. An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.
Vanegas-Arroyave N; Caroff SN; Citrome L; Crasta J; McIntyre RS; Meyer JM; Patel A; Smith JM; Farahmand K; Manahan R; Lundt L; Cicero SA
CNS Drugs; 2024 Apr; 38(4):239-254. PubMed ID: 38502289
[TBL] [Abstract][Full Text] [Related]
6. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers.
Chung WK; Hwang I; Kim B; Jung J; Yu KS; Jang IJ; Oh J
Clin Transl Sci; 2023 Mar; 16(3):512-523. PubMed ID: 36514192
[TBL] [Abstract][Full Text] [Related]
8. Movement disorders of the mouth: a review of the common phenomenologies.
Ghadery CM; Kalia LV; Connolly BS
J Neurol; 2022 Nov; 269(11):5812-5830. PubMed ID: 35904592
[TBL] [Abstract][Full Text] [Related]
9. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice.
Hauser RA; Meyer JM; Factor SA; Comella CL; Tanner CM; Xavier RM; Caroff SN; Lundt L
CNS Spectr; 2022 Apr; 27(2):208-217. PubMed ID: 33213556
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Pharmacology of Tardive Dyskinesia.
Caroff SN
Clin Psychopharmacol Neurosci; 2020 Nov; 18(4):493-506. PubMed ID: 33124584
[TBL] [Abstract][Full Text] [Related]
11. Overcoming barriers to effective management of tardive dyskinesia.
Caroff SN
Neuropsychiatr Dis Treat; 2019; 15():785-794. PubMed ID: 31040678
[TBL] [Abstract][Full Text] [Related]
12. Treatment Recommendations for Tardive Dyskinesia.
Ricciardi L; Pringsheim T; Barnes TRE; Martino D; Gardner D; Remington G; Addington D; Morgante F; Poole N; Carson A; Edwards M
Can J Psychiatry; 2019 Jun; 64(6):388-399. PubMed ID: 30791698
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.
Ward KM; Citrome L
Neurol Ther; 2018 Dec; 7(2):233-248. PubMed ID: 30027457
[TBL] [Abstract][Full Text] [Related]
14. Tardive Dyskinesia Associated with Bupropion.
Tuman TC; Çakır U; Yıldırım O; Camkurt MA
Clin Psychopharmacol Neurosci; 2017 May; 15(2):194-196. PubMed ID: 28449571
[TBL] [Abstract][Full Text] [Related]
15. Experimental treatment of antipsychotic-induced movement disorders.
Shireen E
J Exp Pharmacol; 2016; 8():1-10. PubMed ID: 27540314
[TBL] [Abstract][Full Text] [Related]
16. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
O'Brien CF; Jimenez R; Hauser RA; Factor SA; Burke J; Mandri D; Castro-Gayol JC
Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.
Greenbaum L; Lerer B
Front Neurol; 2015; 6():27. PubMed ID: 25750634
[TBL] [Abstract][Full Text] [Related]
18. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
Yoshida K; Bies RR; Suzuki T; Remington G; Pollock BG; Mizuno Y; Mimura M; Uchida H
Schizophr Res; 2014 Mar; 153(1-3):184-8. PubMed ID: 24491908
[TBL] [Abstract][Full Text] [Related]
19. Atypical antipsychotic-induced metabolic disturbances in the elderly.
Guenette MD; Chintoh A; Remington G; Hahn M
Drugs Aging; 2014 Mar; 31(3):159-84. PubMed ID: 24477569
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
